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The outcomes of patients with metastatic/inoperable gastrointestinal 
stromal tumors (GIST) treated with imatinib 
-  an interim multicenter analysis of Polish Clinical GIST Registry
Włodzimierz Ruka1, Piotr Rutkowski1, Zbigniew Nowecki1,
Czesław Osuch2, Elżbieta Starosławska3, Andrzej Rozmiarek4, Marek Krawczyk5,
Paweł Nyckowski5, Maria Błasińska-Morawiec6, Agnieszka Jagiełło-Gruszfeld7, 
Stanisław Góźdź8, Anna Nasierowska-Guttmejer9, Urszula Grzesiakowska10,
Beata Utracka-Hutka11, Wanda Michej9
T h e  aim . o f the study was to analyze the clinical outcomes o f imatinib treatment in inoperable/metastatic gastrointestinal 
stromal tumors (GIST) CD 117(+) in Polish institutions collaborating in the Clinical G IST Registry.
M a t e r i a l  a n d  m e t h o d s .  Complete basic demographic and clinical data was available in 165 advanced 
(inoperable/metastatic -  M1) patients treated with imatinib in a dose o f400-800 mg (155patients for survival analysis) between 
09/2001 and 01/2005 and registered in the Clinical G IST Registry in Warsaw. This data was compared with that o f 107patients 
without evidence o f recurrent disease (M0) followed-up at the M. Sklodowska-Curie Memorial Cancer Center -  Institute o f 
Oncology in Warsaw.
Re s u l t s .  We observed the prevalence o f male patients in the M1 group as compared to M0 patients (p=0.001). We found  
significantly higher median tumor size (11 cm) and median mitotic count value (10/50 HPF) in M1 patients as compared to 
the M0 group (5.5 cm and 2/50HPF, respectively) [p<0.001]. The percentage o f gastric location (together with the lower 
esophagus and duodenum) was significantly lower in the M1 group than in the M0 group, 36% and 61% respectively 
(p=0.01). In the group o f 155patients treated with imatinib due to inoperable/metastatic lesions, 141 (91%) were alive at the 
time o f the last evaluation in 01/2005. Ten patients (6.5%) demonstrated complete remission o f disease and the other 102 pts 
(66%) remained on imatinib treatment and have maintained disease with partial response (40%) or stabilization (26%) only 
according to REC IST criteria. The estimated 3-year overall and progression-free survival was 75% and 64.5%, respectively. 
C o n c l u s i o n s .  It has been shown that it was possible to achieve a satisfactory clinical outcome in patients with such a rare 
malignancy as G IST  treated with new molecular targeted therapy in different regional cancer centers in Poland. Direct 
multidisciplinary collaboration between specialists caring for patients with G IST in Poland has shown and confirmed the 
outstanding role o f the Polish Clinical G IST  Registry.
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Przeżycia chorych na rozsiany i nieoperacyjny GIST leczonych imatinibem  
-  analiza etapowa Klinicznego Rejestru GIST
C e l e m  badania była analiza wyników leczenia chorych na nieoperacyjny/rozsiany nowotwór podścieliskowy przewodu 
pokarmowego (GIST) CD 117(+), leczonych imatinibem w polskich ośrodkach współpracujących w Rejestrze Klinicznym 
GIST.
M a t e r i a ł  i me t ody .  Kompletne podstawowe dane demograficzne i kliniczne uzyskano u 165 chorych z  zaawansowanym 
G IST (nieoperacyjnym/rozsianym -  M1), leczonych imatinibem w dawce 400-800 mg (155 chorych poddano analizie 
przeżycia) w okresie 09/2001 -  01/2005 i włączonych do Rejestru Klinicznego G IST w Warszawie. Dane te porównano ze 107 
chorymi bez cech nawrotu choroby (M0), poddanych obserwacji w Centrum Onkologii -  Instytucie w Warszawie.
Wy n i k  i. Obserwowano przewagę płci męskiej w grupie M1 w porównaniu z  M0 (p=0,001). Stwierdzono istotnie większą 
medianę wielkości guza (11 cm) i indeksu mitotycznego (10/50 HPF) u chorych w stopniu M1 niż u chorych w grupie M0 
(odpowiednio: 5,5 cm i 2/50 HPF) [p<0,001]. Odsetek chorych na GIST, których pierwotny guz umiejscowiony był w żołądku 
(łącznie z  dolnym odcinkiem przełyku i dwunastnicą), był znacząco mniejszy w grupie M1 niż M0 (odpowiednio: 36 i 61%; 
p  = 0,01). W  grupie 155 chorych leczonych imatinibem z  powodu rozsianych/nieoperacyjnych zmian 141 (91%) żyło 
w 01/2005. U 10 chorych (6,5%) obserwowano całkowitą odpowiedź na leczenie, a dalszych 102 (66%) było leczonych 
imatinibem po uzyskaniu częściowej remisji (40%) lub stabilizacji (26%) choroby zgodnie zkryteriami RECIST. Oszacowane 
3-letnie przeżycia całkowite i wolne od progresji choroby wyniosły odpowiednio 75% i 64,5%.
Wn i o s k i .  Wykazano, że możliwe jest uzyskanie satysfakcjonujących klinicznych wyników leczenia chorych z  tak rzadkim 
nowotworem, ja k  G IST  za pomocą nowoczesnej terapii celowanej molekularnie w różnych regionalnych ośrodkach 
onkologicznych w Polsce. Ścisła wielodyscyplinarna współpraca specjalistów zajmujących się chorym na G IST w Polsce 
potwierdziła istotną rolę Rejestru Klinicznego GIST.
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Introduction
In August 2001 the EORTC trial No. 62005 at the 
Institute of Oncology in Warsaw for the recruitment of 
patients with inoperable/m etastatic gastrointestinal 
stromal tumors (GIST) with positive immunostaining 
for c-KIT (CD117) was opened. At that time the trial 
was the third in the world (and the first conducted in 
Poland) -  a prospective, randomized study evaluating the 
efficacy of molecular targeted treatm ent of GIST with 
small-molecule tyrosinase kinase inhibitor -  imatinibe 
mesylate. Patient recruitment was finished in February 
2002. The preliminary results of the study were published 
during the Annual Society of Clinical Oncology Annual 
Meetings 2003 and 2004, and finally were published in 
2004 [1]. Soon after entering first patients we had realized 
that the treatm ent of GIST patients is an effort of many 
specialists throughout Poland: pathologists, surgeons, 
oncologists and radiologists. To strike up closure 
cooperation, the Polish Clinical GIST Registry was 
organised in 2002 as a multidisciplinary forum  for 
exchanging inform ation about GIST treatm ent and 
research. It holds national meetings twice a year in 
different centers in Poland. The main points of interest of 
the Clinical GIST Registry are: propagation of knowledge 
about GIST (diagnosis/treatment); clinical data collection, 
analysis of treatment outcomes, analysis of co-existence of 
other neoplasms in GIST patients, the evaluation of the 
role of surgery after imatinib treatment and co-operation 
in clinical trials and molecular research. The main 
achievement of our Registry is the extension of awareness 
of the GIST disease among doctors and the increase of
newly diagnosed cases of GIST in Poland, as well as the 
im plem entation of new, effective treatm ent of this 
malignancy, as is the case in other European countries. 
The aim of this study is to analyze the clinical outcomes of 
imatinib treatm ent in inoperable/metastatic GIST CD 
117( + ) in Polish centers collaborating in the Clinical 
GIST Registry.
Material and method
We have collected data related to inoperable and/or metastatic 
G IST patients treated  with imatinib from all institutions 
participating in the Clinical GIST Registry -  oncological 
centers throughout Poland -  at the beginning of January 
2005. The inform ation was obtained from the centers with 
the aid of a special questionnaire published on the web page 
(http://www.coi.waw.pl) and sent by e-mail (gist@coi.waw.pl) 
or fax. There were 98 patients treated at the Maria Sklodowska- 
Curie M em orial Cancer C enter and Institu te of Oncology 
(CCIO) in Warsaw and 103 patients in o ther Polish centers. 
Complete basic demographic and clinical data was available in 
case of 165 advanced patients trea ted  with imatinib and 
registered in the Clinical GIST Registry in Warsaw. These data 
were compared with that of 107 patients without evidence of 
recurrent disease followed-up in the CCIO in Warsaw (Table I).
The criteria of eligibility for imatinib treatm ent were as 
follows:
-  histological diagnosis of GIST,
-  c-Kit (CD117) positive staining (Dako polyclonal antibodies),
-  metastatic and/or inoperable lesions,
-  measurable disease on computed tomography scans,
-  WHO performance status <3,
-  no concomitant therapy for disease,
-  adequate renal and liver function.
197
Table I. Patient characteristics (groups: M l -  patients with inoperable/metastastatic GIST lesions treated with imatinib; 
M0 -  patients without evidence of disease, follow-up only)
Clinicopathological feature M1 M0 Total p-value
165 pts 107 pts 272 pts
Age [years] Range
M ean
M edian
17-83 years 
56 years 
56 years
23-85 years 
58 years 
60 years
17-85 years
57 years
58 years n.s.
Gender Female
M ale
69 (41.8%) 
96 (52.8%)
66 (61.6%) 
41 (38.4%)
135 (49.6%) 
137 (50.4%) p=0.001
Primary tum or site Esophagus
Stomach
Duodenum
Small bowel
Large bowel/rectum
Retroperitoneal space
Others, intraperitoneally with
Unknown primary origin
2 (1%) 
50 (30%) 
8 (5%) 
60 (36%) 
12 (7%) 
14 (9%)
19 (12%)
58 (54%) 
7 (7%) 
34 (31%) 
2 (2%) 
2 (2%)
4 (4%)
2 (0.7%) 
108 (39.7%)
15 (5.5%) 
94 (34.6%) 
14 (5.1%)
16 (5.9%)
23 (8.5%) p<0.001
Tumor size [cm]
M ean
M edian
104 pts 
13 cm 
11 cm
80 pts 
7 cm 
5.5 cm p<0.001
Mitoses number in 50 High Power Fields
M edian
48 pts 
10
44 pts
2 p<0.001
Time to recurrence after primary 
operation R0/R1
Range
M ean
Median
96 pts 
1 -  182 
24 months 
13 months
Follow-up time
Range
M ean
Median
104 pts 
1 -  132 
18 months 
12 months
Pts = patients
Imatinib treatm ent started from the dose of 400 mg once 
daily orally. The response to treatm ent was evaluated according 
to the RECIST criteria with computed tom ography imaging 
examinations performed every 2-3 months. In case of progres­
sion the dose was increased to 600-800 mg daily. In case of 
further progression imatinib treatm ent was stopped. The 
imatinib dose was reduced to 300 mg daily due to recurrent 
grade 3 toxicity (neutropenia) in 2 cases.
For statistical computations the contingency tables were 
analyzed by the chi-square test. Groups were compared for age 
differences using the t-test for normal distribution of parameters 
and for o ther param eters, with non-norm al distribution the 
Mann-Whitney U -test was used. Differences were considered 
statistically significant if p-values were <0.05. The Kaplan-Meier 
method was used for the analysis of survival curves. Overall 
survival (OS) and progression-free survival (PFS) time were 
calculated from the date of start of imatinib treatm ent to the 
date of the most recent follow-up, progression or death (for 
PFS and OS, respectively). 14 patients were excluded from the 
survival analysis because of the lack of detailed dates of the 
start of imatinib treatm ent. We excluded further 32 patients 
because of a too short follow-up time (minimal follow-up time 
necessary for the evaluation of the results of treatm ent was 6 
months, which means that imatinib treatm ent should have been 
started before June 31st, 2004). Finally, for the survival analysis, 
we included 155 GIST patients treated  with imatinib from 
09/2001 to 01/2005. Median follow-up time was 17.7 months for 
survivors and mean follow-up time -  19 months. For data
collection the hospital information system ONCOsys and the 
Clinical GIST Registry databases were used.
Results
The characteristics of the group of c-KIT positive GIST 
patients with inoperable/metastatic lesions treated with 
imatinib (group M1) and patients followed-up without 
evidence of recurrent disease after radical operation 
(group M0) are shown in Table I. Median age in the M1 
group was 56 years and in the M0 group -  60 years 
(p = 0.2). Men comprised the majority of patients in the 
inoperable/metastatic group, but, on the contrary, women 
predom inated among patients w ithout recurrence of 
disease after primary surgery (p = 0.001).
The median tum or size (11 cm) was significantly 
higher in the M1 group as compared to the M0 group 
(5.5 cm) [p<0.001]. Similarly, the median mitotic count 
value was significantly higher in the M1 group 
(10/50HPF) than in the M0 group (2/50HPF) [p<0.001].
The characteristics of GIST locations were different 
in the M1 and M0 groups. The percentage of gastric 
locations (together with the lower esophagus and 
duodenum) was clearly lower in the M1 group than in
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the M0 group, 36% and 61% respectively. On the 
contrary, the percentage of bowel GIST locations (small 
and large together) is significantly higher in the M1 group 
as compared to the M0 group, 43% and 33% respectively
(p=0.01).
The median time to GIST recurrence was 13 months 
in the M1 group and was comparable to the median time 
of 12 months of follow-up in the M0 group. It means that 
the lack of recurrence in the M0 group was not related to, 
or caused by, the shorter time of follow-up only (Table I).
We have also observed a relatively high ratio of 
a second co-existent malignant neoplasm (8.1%) in the 
past history of GIST patients (8.5% -  14/165 in M1 and 
7.5% -  8/107 in M0 groups).
In the group of patients with inoperable/metastatic 
lesions (M1) only two cases of dissemination outside the 
abdominal cavity (one to the bones and one to the lungs) 
were found. All patients in this group have had liver 
metasteses or in traperitoneal dissem ination and, 
sometimes, inoperable local recurrences or prim ary 
tumors (data not shown).
In the eligible for analysis group of 155 patients 
treated with imatinib due to inoperable/metastatic lesions, 
141 (91%) were alive at the time of the last evaluation 
in January 2005. Ten patients (6.5%) dem onstrated 
complete remission of disease and the other 102 pts 
(66%) remained on imatinib treatm ent and have main­
tained disease with partial response (40%) or stabilization 
(26%) only according to RECIST criteria. Disease 
progression was observed in 27.5% of patients. Detailed 
results of imatinib treatm ent are presented in Table II.
Table II. The evaluation of response to imatinib treatment in 155 
GIST patients (median follow-up 17.7 months)
Result No of patients %
Com plete remission (CR) 10 6.5%
Partial remission (PR) 62 40.0%
Stable disease (SD) 40 26.0%
Progressive disease (PD) 43 27.5%
Tim e [m onths]
Figure. 1. Overall (OS) and progression-free (PFS) survival of patients 
treated with imatinib
Nineteen patients underwent adjuvant radical surgery 
after partial/complete response obtained during imatinib 
treatment. The estimated 3-year overall and progression- 
free survival were 75% and 64.5%, respectively (Figure 1).
The adverse events were ra ther frequent during 
imatinib treatment, but most of them were mild (grade 
1-2). The most common were: fluid retention, edema, 
nausea, abdominal and muscle pain, diarrhea and anemia. 
We observed some cases of grade 3-4 toxicity: neutropenia 
(4 cases), ascites (2 cases), skin rash (2 cases), tumor 
hemorrhage requiring surgery (1 case) and soft tissue 
infection in 2 cases (data not shown).
Discussion
Gastrointestinal stromal tumors (GIST) comprise a re­
cently defined entity of the most common mesenchymal 
neoplasms of the abdominal cavity. GIST is thought to 
arise from precursors shared with the normal interstitial 
cells of Cajal -  the gut pacemaker cells. They are charac­
terized by overexpression of m utated c-KIT receptor 
detected by CD117 immunostaining [2, 3]. The intro­
duction of molecular targeted therapy with imatinib 
mesilate has focused attention on GIST patients [4-7]. 
The current study presents the first multicenter results 
of treatm ent of inoperable/metastatic GIST patients in 
Poland.
GISTs occur in both genders with a more or less 
similar frequency, but among patients with inopera­
ble/metastatic disease we observed male predominance. 
The m edian age of patients was 55-60 years but, 
unexpectedly, patients with inoperable/metastatic GIST 
were slightly younger than those w ithout disease 
recurrence after radical primary surgery. The tumor size 
and the m itotic count, considered to be the most 
important prognostic factors, were significantly higher in 
the metastatic/inoperable group as compared to the non­
recurrent group. This “advanced patients” group also 
comprised a lower percentage of gastric GISTs, which 
are considered to possess a lower recurrence potential 
[3, 8]. In general, all the listed clinical and pathological 
factors could play a crucial role in GIST prognostification 
(Table III). Undoubtedly, the quality of GIST surgery
Table III. Probable prognostic factors in GIST patients
Param eter Category .
tum or size <5 cm vs. >5 cm
mitotic rate <5/HPF vs. >5/H PF
tum or location stomach vs. other
gender female vs. male
age (as continuous variable) older vs. younger
mutation type KIT (exon 11,9, other, WT) vs. PD G FR
type of surgery R0 vs R1
H PF -  high power field; WT -  wild type; PD G FR  -  Platelet-derived 
growth factor receptor
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should also play a crucial role in GIST patients prognosis 
[9].
The incidence of the registered advanced and 
aggressive (inoperable/metastatic) cases in Poland may 
be estimated at approx. 3 new cases per million annually, 
which means that according to statistics 1 case per 
a million of inhabitants per year is still not registered. 
The reliable data on the incidence of GIST are still not 
fully available, but the real number of all GIST cases in 
many countries is underestimated [8, 10, 11].
Imatinib mesylate therapy is the first and only one 
effective nonsurgical treatm ent for GIST. Imatinib 
mesylate prevents kinase signaling by blocking (in GIST) 
the KIT-associated signaling cascade. Several clinical trials 
have now been conducted to confirm the dram atic 
efficacy of imatinib in the treatment of GIST in a majority 
of patients with inoperable/metastatic disease [4, 6, 10]. 
When compared to historical clinical data, in which the 
median survival of those patients was 10-12 months, the 
m ethod is really superior (in our group of patients 
the median survival has not been reached after a median 
follow-up time of almost 18 months and the estimated 
3-year progression-free survival was 64.5%). However, 
imatinib is not a panaceum  for GIST patients -  with 
a longer follow-up time the rate of patients who have 
progressive or are resistant to imatinib increases and 
complete remission is rare (<10% ). This implies 
the necessity for further studies on new drugs in 
resistant cases (SU11248 and AM G 706 are currently 
evaluated in the clinical setting) and, what is more 
important, on the combination of imatinib therapy with 
surgery [10].
The most effective method of response evaluation is 
com puted tom ography imaging, but the criteria of 
response are rather controversial and unsatisfactory and 
should be reconsidered [1].
The role of imatinib therapy in the adjuvant and 
neoadjuvant setting has not yet been established and is 
being evaluated in clinical trials (ACOSOG Z900 and 
Z9001; RTOG 0132 and EORTC 62024). The optimal 
dose for this orally administered, well-tolerated agent is 
still under discussion. There are some arguments that 
dose dependency (400 mg vs 800 mg) of the response to 
imatinib is related to the mutational status of the tumors 
and their localization (stomach vs small bowel) [12]. In 
patients with disseminated bowel GIST not responding to 
the 400 mg dose it appears to be justified to administer 
800 mg daily doses.
In our paper it has been shown that it is possible to 
achieve a satisfactory clinical outcome in patients with 
such a rare malignancy as GIST treated  with new 
molecular targeted therapy in different regional cancer 
centers in Poland. Direct multidisciplinary collaboration 
between specialists caring for patients with GIST in 
Poland has shown and confirmed the outstanding role of 
the Polish Clinical GIST Registry.
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